Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD123-CD33 cCAR in Hematologic Malignancies
NCT04156256Phase 1Unknown
- Sponsor
- iCell Gene Therapeutics
- Start
- Mar 2018
- Primary completion
- Sep 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD33/CD123 bispecific Chimeric Antigen Receptor T cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Myeloproliferative Neoplasm (MPN) and 1 more, sponsored by iCell Gene Therapeutics. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 2 years. Status: unknown.
02
Drugs
CD33/CD123 bispecific Chimeric Antigen Receptor T cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04156256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156256.